XNCR Xencor Inc

Price (delayed)

$23.82

Market cap

$1.46B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.08

Enterprise value

$1.49B

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 20 candidates engineered with Xencor's XmAb® technology are in ...

Highlights
The gross profit has increased by 16% from the previous quarter and by 2.3% YoY
XNCR's revenue is up by 16% since the previous quarter and by 2.3% year-on-year
The company's net income has shrunk by 128% YoY and by 6% QoQ
The EPS has shrunk by 124% YoY and by 4% QoQ

Key stats

What are the main financial stats of XNCR
Market
Shares outstanding
61.12M
Market cap
$1.46B
Enterprise value
$1.49B
Valuations
Price to book (P/B)
2.17
Price to sales (P/S)
8.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.82
Earnings
Revenue
$168.34M
EBIT
-$120.28M
EBITDA
-$108.78M
Free cash flow
$66.66M
Per share
EPS
-$2.08
Free cash flow per share
$1.1
Book value per share
$10.99
Revenue per share
$2.78
TBVPS
$15.44
Balance sheet
Total assets
$952.69M
Total liabilities
$283.56M
Debt
$83.43M
Equity
$668.8M
Working capital
$538.45M
Liquidity
Debt to equity
0.12
Current ratio
7.36
Quick ratio
7.15
Net debt/EBITDA
-0.27
Margins
EBITDA margin
-64.6%
Gross margin
100%
Net margin
-74.9%
Operating margin
-82.4%
Efficiency
Return on assets
-15.2%
Return on equity
-18.7%
Return on invested capital
-15.8%
Return on capital employed
-13.9%
Return on sales
-71.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

XNCR stock price

How has the Xencor stock price performed over time
Intraday
3.79%
1 week
-2.66%
1 month
24.97%
1 year
-26.78%
YTD
12.2%
QTD
12.2%

Financial performance

How have Xencor's revenue and profit performed over time
Revenue
$168.34M
Gross profit
$168.34M
Operating income
-$138.64M
Net income
-$126.09M
Gross margin
100%
Net margin
-74.9%
The company's net income has shrunk by 128% YoY and by 6% QoQ
Xencor's net margin has shrunk by 124% YoY but it has increased by 9% QoQ
Xencor's operating income has plunged by 68% YoY but it has increased by 5% from the previous quarter
XNCR's operating margin has dropped by 64% year-on-year but it is up by 18% since the previous quarter

Growth

What is Xencor's growth rate over time

Valuation

What is Xencor stock price valuation
P/E
N/A
P/B
2.17
P/S
8.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.82
The EPS has shrunk by 124% YoY and by 4% QoQ
XNCR's P/B is 25% below its 5-year quarterly average of 2.9 but 3.3% above its last 4 quarters average of 2.1
XNCR's equity is down by 8% year-on-year
XNCR's P/S is 36% below its 5-year quarterly average of 13.3 and 26% below its last 4 quarters average of 11.6
XNCR's revenue is up by 16% since the previous quarter and by 2.3% year-on-year

Efficiency

How efficient is Xencor business performance
XNCR's ROE has plunged by 149% YoY and by 8% from the previous quarter
The ROA has plunged by 134% YoY and by 2.7% from the previous quarter
The ROIC has plunged by 116% YoY but it has grown by 3.1% from the previous quarter
The ROS has shrunk by 116% YoY but it has increased by 13% QoQ

Dividends

What is XNCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XNCR.

Financial health

How did Xencor financials performed over time
XNCR's total liabilities has surged by 159% since the previous quarter and by 139% year-on-year
The company's current ratio fell by 32% QoQ and by 30% YoY
Xencor's debt is 88% lower than its equity
The debt to equity has soared by 50% YoY and by 33% from the previous quarter
Xencor's debt has increased by 40% YoY and by 37% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.